IBS Videos

Talking To Your Doctor About IBSWe understand that talking to your doctor about IBS is uncomfortable, because we are patients too, but having open and honest communication with your care team is incredibly important. If you aren’t sure where to start, in partnership with Tuesday Night IBS we have prepared some videos to help you make the most of your appointments. >> View the complete video series

Food Sensitivity and Tools to Live Better Webinar - Tuesday Night IBS Kate Scarlata, MPH, RDN who is a clinical expert in the research and practical use of FODMAP for managing GI symptoms, invited four companies to speak about their products to help you make food choices easier. This independent medical educational webinar is supported by Intoleran, Gourmend Foods, tuut Inc, and Verve Market https://vimeo.com/1213664329 or on the TuesdayNightIBS.com website.

FDA Expansion of Linaclotide for Children 2-5 Years With Functional Constipation HCPLive On May 27, 2026, Ironwood Pharmaceuticals' linaclotide (Linzess) received expanded approval from the US Food and Drug Administration (FDA) for pediatric patients aged ≥2 years with functional constipation (FC). Previously approved for FC in children aged ≥6 years, the expanded indication extends access to linaclotide for children aged 2–5 years with FC. Linaclotide remains the only FDA-approved prescription therapy for pediatric FC. “Functional constipation is one of the most common conditions we treat, and younger children unfortunately have very limited evidence-based treatment opt…

Rethinking IBS Management: The Shift Toward Precision Care, With Ali Rezaie, MD HCPLive Rezaie explains how IBS care has shifted from symptom-based treatment to targeted, mechanism-driven strategies. Irritable bowel syndrome (IBS) remains one of the most common but complex disorders in gastroenterology, historically characterized by a symptom-based diagnosis and broad treatment strategies. However, growing insight into its diverse underlying mechanisms has prompted a shift in how clinicians approach management. In an interview with HCPLive, Ali Rezaie, MD, highlighted how instead of relying solely on empiric, symptom-driven care, today’s paradigm increasingly emphasizes …

Are We Overlooking Long-Term Risks in IBS Management? New 20-Year Safety Data, With Ali Rezaie, MD HCPLive Management of irritable bowel syndrome (IBS) has undergone a notable evolution in recent decades, shifting from largely empirical, symptom-based treatment toward a more nuanced, mechanism-driven approach. However, as clinicians increasingly rely on long-term pharmacotherapy for a condition often diagnosed in early adulthood, questions around the durability and safety of these treatments have come into sharper focus. A recent large-scale study led by Ali Rezaie, MD, medical director of the GI Motility Program at Cedars-Sinai, sought to address a critical gap in the l…

Gut Serotonin and Bloating Relief, What New Research Shows NCHStats Most people think serotonin lives in the brain—but about 90% of it is made in the gut! In this video, Dr. Stephen Wangen explains how the gut and microbiome regulate serotonin, how this affects mood and digestion, and what you can do to naturally support both your gut and your mental well-being. Learn how the gut-brain connection truly works and why healing your gut may be the key to better emotional health. View the full article

Nearly One-Third of IBS Patients Report Gluten Sensitivity, New Study Finds (Video) celiac.com A large Italian study finds that nearly 30% of young adults with irritable bowel syndrome also report noncebiac gluten sensitivity, with more who-body symptoms and higher use of gluten-free diets. View the full article

Your Poop Schedule Says a Lot About Your Overall Health, Study Reveals ScienceAlert "How often do you poop?" might sound like a very personal question, but your answer could reveal quite a lot about your overall health. A study published in 2024 investigated how often people had bowel movements and compared those stats to their demographic, genetic, and health data. The healthiest people among the 1,425 participants reported pooping once or twice a day – a 'Goldilocks zone' of bowel movement frequency. Pooping too often or too rarely was associated with different underlying health issues, the team led by researchers at the Institute for Systems Biology (ISB) found. "This…

The role of probiotics in the care of IBS and other GI conditions Probiotics could help manage IBS symptoms like bloating, gas, and abdominal pain by balancing gut flora, strengthening the gut barrier, and improving motility, Benefits vary by strain and individual. Our GI experts: John Damianos MD a clinical fellow in Gastroenterology and Hepatology at the Mayo Clinic who also serves on the Scientific Advisory Committee of the Alliance for Education on Probiotics and Kate Scarlata MPH, RDN a clinical expert in the research and practical use of diet and FODMAP for managing GI symptoms, will be discussing this topic. >> Watch recording

Are gravity and IBS related? We had a discussion about a new theory related to gravity and how could it be shaping our guts, minds and stomachs. Dr. Spiegel was joined by Dr. Megan Riehl, PsyD and Kate Scarlata, MPH, RDN to unravel if gravity could actually be shaping our guts, minds and stomachs and might IBS be a symptom of this dysregulation. >> Watch recording

Estrogen found to trigger gut pain, explaining higher IBS rates in women: Study Medical Dialogues For years, scientists have known that women are far more likely than men to suffer from irritable bowel syndrome (IBS)-a chronic disorder marked by abdominal pain, bloating, and digestive distress. But why has remained a mystery. Now, researchers from UC San Francisco may have found the answer. In a study published in Science, the team discovered that estrogen directly activates pain pathways in the colon, making the female gut more sensitive to certain foods and inflammation. Working with mouse models, the team led by Dr. Holly Ingraham and Nobel laureate Dr. David Julius b…

Real-World Data Highlight a New Approach to Chronic Constipation, With Darren Brenner, MD HCPLive Brenner describes shortcomings of pharmacologic CIC options and reviews real-world data on the Vibrant System’s benefits in this context. Chronic idiopathic constipation (CIC) remains one of the most challenging and heterogenous disorders encountered in GI practice. While clinicians today have a wide therapeutic armamentarium, including osmotic and stimulant laxatives, secretagogues, and prokinetic agents, each option carries limitations and side effects that impede adherence and patient satisfaction. Against this backdrop, the vibrating capsule (Vibrant System) represents …

Tuesday Night IBS was joined by two gastroenterologists to discuss the IBS-C Treatment and Management in adults and children. The webinar featured Dr. Kyle Staller, an adult gastroenterologist, and Dr. Thomas Wallach, a pediatric gastroenterologist. Learn more about how IBS-C is being managed in adults and children and whether you should discuss new treatments with your own doctor. >> Watch recording

SIBO, IBS, Constipation and Diarrhea - Tuesday Night IBS Sharing new insights, research, testing advances, and treatment approaches Watch: https://vimeo.com/1139641467 Recorded on: November 19, 2025 Guest expert: Dr. Mark Pimentel, Cedars-Sinai, Los Angeles Moderated by: Jeffrey Roberts MSEd, BSc This independent medical educational webinar was supported by Ardelyx, Inc.

Is it IBS or a virus? Signs that help you know the difference News 9 Dr. Lacy Anderson explains sudden, short-term nausea and vomiting signal a stomach virus, while long-lasting bowel issues point to IBS, which may require treatment and further evaluation. View the full article

Julie Khlevner, MD, AGAF, explains the impact of the FDA approval of linaclotide for pediatric IBS-C Contemporary Pediatrics Pediatric gastroenterologists now have a newly approved treatment option for children and adolescents with irritable bowel syndrome with constipation (IBS-C) following the FDA’s recent approval of linaclotide (Linzess) capsules for patients ≥7 years of age. This approval marks the first pharmacologic therapy for IBS-C in this population, expanding on linaclotide’s prior approvals for chronic idiopathic constipation and functional constipation in children. Julie Khlevner, MD, AGAF, associate professor of Pediatrics at Columbia University Medical Ce…

Discussing Safety, Tolerability of Tenapanor in Pediatric IBS-C patients, with Thomas Wallach, MD HCPLive At the 2025 North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN), held in Chicago, Illinois, investigators presented new interim safety findings from the phase 3 R-ALLY trial and its open-label extension evaluating tenapanor in pediatric patients with irritable bowel syndrome with constipation (IBS-C). Preliminary data demonstrated that tenapanor, a first-in-class sodium/hydrogen exchanger isoform 3 (NHE3) inhibitor, was safe and well-tolerated among adolescents, with no serious treatment-related adverse events reported. “Tenapa…

Lin Chang, MD, on IBS and Pregnancy HMP Global Learning Network Hormonal impact on GI motility and reflux: Elevated estrogen and progesterone during pregnancy relax GI smooth muscle, slowing intestinal transit and relaxing the lower esophageal sphincter. This leads to early-onset constipation and GERD symptoms—often beginning by the end of the first trimester, independent of uterine size. IBS and pregnancy outcomes: Limited data show women with irritable bowel syndrome (IBS) may have a ~20% higher miscarriage risk versus non-IBS controls, but most experience stable or improved symptoms during pregnancy. Further research is needed to clarify IBS course and outcomes in pr…

Psychedelics Show Promise in Treating IBS and Gut-Brain Disorders Docwire News Erin Mauney, MD, of Tufts Medicine, discusses her pioneering work applying psilocybin-assisted therapy to irritable bowel syndrome (IBS) and other gut-brain disorders. Drawing from both emerging clinical trial evidence and the lived experiences of patients, Dr. Mauney explains how psychedelics may help individuals process trauma, reconnect with their bodies, and reduce chronic pain symptoms. Although widespread clinical use in the US may still be years away, her team’s research is opening new doors for mind-body approaches to gastrointestinal and obesity medicine. View the full article

Amber Tresca had the pleasure of speaking with Dr. Katie Dunleavy, a gastroenterologist from Boston who specializes in IBD. Dr. Dunleavy’s journey from operatic performance to medicine is as fascinating as her insights into IBD are invaluable. Topics discussed on this episode: ✅ Definition and overview of inflammatory bowel disease (IBD) ✅ Differences between IBD and irritable bowel syndrome (IBS) ✅ Types of IBD: Crohn's disease, ulcerative colitis, indeterminate colitis, and microscopic colitis ✅ Common symptoms associated with IBD ✅ Diagnostic processes and tests for IBD ✅ Treatment options and the importance of personalized care ✅ Role of diet and lifestyle chang…

Cutting Edge Science: Dietary Treatment of IBSDr. Heinz Hammer, MD Associate Professor of Internal Medicine and Gastroenterology, Medical University Graz, Austria

Cutting Edge Science: The Which of Dietary Treatment of IBSDr. Heinz Hammer, MD Associate Professor of Internal Medicine and Gastroenterology, Medical University Graz, Austria

Cutting Edge Science: The What of Dietary Treatment of IBSDr. Heinz Hammer, MD Associate Professor of Internal Medicine and Gastroenterology, Medical University Graz, Austria

New Study Aims to Understand Gastrointestinal Anxiety in Celiac and IBS Patients Celiac.com This study shows that anxiety about digestive symptoms is a real and measurable problem—not just in irritable bowel syndrome Celiac.com 08/19/2025 - Many people with digestive conditions, such as irritable bowel syndromeor celiac disease, experience more than physical symptoms. They also deal with anxiety tied to those symptoms—like fear of eating certain foods or going to places without easy restroom access. This kind of anxiety is known as gastrointestinal symptom-specific anxiety. To measure it, researchers often use a tool called the Visceral Sensitivity Index. This study set …

Live from the Lab! - Fresh from presenting multiple studies at the 2025 Digestive Disease Week (DDW) Conference, Dr. Mark Pimentel shared new insights in SIBO and IBS research, testing advances, and treatment approaches – and answered viewer questions during a Live Q&A. About Mark Pimentel, MD: 🔬 Dr. Mark Pimentel is a renowned gastroenterologist and researcher, serving as the Executive Director of the Medically Associated Science and Technology (MAST) program at Cedars-Sinai. He is widely recognized for his pioneering work on IBS and SIBO, having published over 150 scientific papers and authored two books on the subjects. Dr. Pimentel's research has led to significa…